Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Excalibur Healthcare Private and confidential Excalibur • World class track record in medical infrastructure and investments over 30 years • Created over 50 medical and health companies from scratch worth over $5bn • IPO’d 21 companies on worlds stock market • Constructed 270 different laboratories/clinics • Built over 65 office buildings and premises for own companies • Built over 40 advanced manufacturing facilities and production plants • Raised >$2bn for cancer research in 40 areas of cancer • Over 200 new medicines in development • Over 20,000 patients in clinical trials • In 1996 Sir Chris first entrepreneur to develop new stem cell technology in Europe $5 Billion of Value by Sir Chris Evans and Excalibur Team Company Date Chiroscience PLC 2003 $1.0m $1,000m BioVex Inc 2011 $2.0m $1,000m Vectura PLC 2008 $1.5m $1,100m Ark Therapeutics PLC 2007 $2.0m $560m Piramed Limited 2009 $0.5m $200m Neurotech 2011 $0.5m $165m Arakis PLC 2005 $0.4m $160m Celsis International PLC 2008 $0.3m $150m Santhera AG 2007 $5.0m $125m Plethora PLC 2007 $0.1m $120m Wilex AG 2007 $7.0m $120m Noxxon AG 2011 $6.0m $120m ReNeuron PLC 2006 $1.0m $100m Cyclacel Inc 2003 $3.0m $90m Neuropharm PLC 2007 $0.2m $75m Microscience Limited 2006 $1.0m $65m Toad PLC 2000 $0.1m $65m Virgin Health Bank Limited 2010 $2.0m $45m Derms Development Limited 2007 $4.0m $45m Energist Limited 2010 $5.0m $35m Destination Skin Limited 2008 $3.0m $35m Cambridge Biotechnology Limited 2007 $0.5m $25m $46.1m $5,500m TOTAL Initial Value Peak Value Leadership EHC is led by Professor Sir Christopher Evans OBE, Europe’s foremost biosciences, medical and healthcare entrepreneur who has: • Advised four UK Prime Ministers on biomedical and healthcare policy • Chaired the EU “BEST” Taskforce overseeing 19 million small businesses across the European Union • Advised the governments in London, Wales, Denmark, Finland, Malta and Qatar • Led the creation and growth of several billion dollars’ worth of advanced medical companies • Built this team of UK experts to provide medical facilities and services, to advise on setting health care policy and a long-term strategy for healthcare needs. Core Consortium Members Globally Recognised UK Based Health Experts The Excalibur Healthcare Consortium • Extensive experience in healthcare facilities construction and management • Delivered over 2500 hospitals, labs, clinics and other healthcare infrastructure globally, including: Primary Healthcare Centres General and Acute Hospitals Specialist and Tertiary Hospitals Mental Healthcare Facilities Medical Research Facilities Specialist Training Facilities • Includes some of the UK’s finest medical experts and practitioners – Royal Colleges, NHS Trusts, leading Universities and Medical Schools. • Enjoys the full support of the UK government through co-operation with UK Trade and Industry (UKTI) and Healthcare UK. The EHC Offering • • • • • • • • • • • • Hospital management and operation Staffing – clinical, technical, support and management staff Strategic direction - improved patient care and outcomes, system efficiencies Mobile primary health care facilities Trauma & rehabilitation Training and education Modular hospitals Refurbishment of existing healthcare facilities Conversion for healthcare use Permanent hospitals State of the art mobile hospitals Medical equipment and pharmaceutical supplies, supply chain management Impact • Improved patient outcomes • Consistently applied protocols and practices • Clinical delivery to highest UK standards • Operational and management efficiency • Sustainability through training and education • Continuing development of local staff Ground Breaking Therapy ReNeuron plc Clinical-stage, UK-based cell therapy business Highly scalable stem cell expansion technology – off-the-shelf (allogeneic) cell therapy candidates Principal therapeutic programs target: stroke disability critical limb ischaemia retinitis pigmentosa Leading position in exosomes Formed and financed 13 years ago by Prof. Sir Chris Evans Led transformative fund raise in summer 2013 Private and confidential 9 BioVex 12 BioVex Inc $1 Billion Medical Technology Cash Raised by Sir Chris and Team for Cancer Research $2.0 billion Cancer – A Global Disease There are over 150 million people living today with cancer There are over 200 different types of cancer and 1 and 3 people on earth will be struck by cancer within their lifetime Every year, nearly 10 million people die of cancer and every year there are nearly 15 million new cases of the disease 1 in 4 of all British deaths are from cancer During the lifetime of this existing global population over 2,000 million people will at some stage have had cancer Cancer must be controlled Private and confidential 19 Cancer - A Commanding Speciality Best elements from the finest Cancer institutions around the world: • • • • Early screening using modern imaging techniques and molecular pathology Rapid diagnosis supported by excellent radiological opinion Ground-breaking therapies, radiology and outpatient chemotherapy delivery “Distributed clinic” model: • national centres of excellence; • local cancer centres, clinics, and mobile clinics • UK leading institutions: • second opinions, knowledge transfer, support and training Private and confidential 20 Countries with National Cancer Plans Source: UICC Private and confidential 21 Cancer in Algeria • Fourteen regional cancer registries covering 37.7% of population • Existing valuable data • Top cancer types identified Male Female Lung Breast Colon-rectum Colon-Rectum Prostate Thyroid Hematopoietic Cervix Bladder Ovaries • A well researched comprehensive National Cancer Plan (NCP) in place Private and confidential 22 Cancer – Key Areas of Improvement The NCP has identified key areas of improvement • Equity • Patient experience • Surveillance • Prevention • Screening • Diagnosis • Therapy • Palliative care • Support Organisations • Regulation • Training • Research • Communication Private and confidential 23 Cancer Plans – Need to be Implemented • The National Cancer Plan puts Algeria in top 20 countries with focus on Cancer Care − Great recommendations and findings • Only top five countries have actually invested in cancer care consistently over many years in an attempt to implement their plans, with mixed results − USA − UK − Sweden − Canada − Australia Challenge: How to short circuit 10 years of talking / planning / meetings and start taking action NOW Private and confidential 24 Optimal Implementation Process High Level Plan for Development of Cancer Services Key Actions Diagnostic to define and assess needs of the health economy Agree principles of early deployment of facilities and cancer services to have a visible impact on the care of patients Roll out mobile diagnostic facilities (wet lease) - example breast screening units, mobile clinics to take cervical smears Build diagnostic facilities in the communities - increase capacity within the CAC rapidly to improve early detection rates Design World Class Cancer Centre drawing from experience for similar institutions internationally Build World Class Cancer Centre that will deliver complete range of high tech diagnostics and specialised therapy. This will form the basis of a hub and spoke model. Deploy World Class Cancer Centre - provides specialised care for a wide range of complex cases with the latest in diagnostics and treatment Procure Staffing for Cancer Centre - specialist pathologists, radiologists, radiographers, surgeons and other support personnel. Potentially internationally to build capacity. Build Therapy Centres - Radiotherapy - existing 7 projects that need to be completed Design Population Surveillance for ongoing information of changing demographic and incidence patterns Develop and Deploy Population Surveillance with appropriate IT support allowing information analysis and data mining Design Screening Programmes - for specific conditions such as cervix, breast, bowel, colo-rectal cancers Roll out Screening Programmes - for specifc conditions such as cervix, breast, bowel, colo-rectal cancers Annual review of surveillance and screening Define national requirements for additional specialised hospitals, diagnostic centres and therapy clinics Develop local clinica - polyclinics, diagnostic facilities Develop post treatment support - after care, rehabilitation following complex surgery Develop and deploy palliative care - for end of life care patients, residential facilities away from hospital Build and deploy additional diagnostic facilities - specialised centres that provide pathology, radiology and in certain cases cytogenetics Build and deploy additional therapy facilities - Radiotherapy units, day case units that can provide chemotherapy drugs as day patients Develop Cancer Networks - to facilitate expert opinions, rapid decisions on diagnosis and management and knowledge sharing Develop existing diagnostic departments (histopathology) - increase the capacity and capability through training of various staff and recruitment of trained staff Understand training needs of various groups of staff such as doctors, primary care physicians, paramedics, radiographers. Develop & Deploy training programmes for undergraduates Develop & Deploy training programme for professionals (medical/paramedical/technical) Develop and implement regulatory frameworks - to support prevention programmes for environmental, lifestyle and occupational risks Develop Research Plans Design and build Research facilities including modern facilities for cyto genetic research Conduct research - existing facilities - large teaching hospitals and specialist centres Operate new research facilities - research into the management of cancers with international cooperation and collaboration Private and confidential 0-3 4-6 7-9 10 - 12 13 - 15 16 - 18 19 - 21 Time Line – Months 22 - 24 25 - 27 28 - 30 31 - 33 34 - 36 37 - 39 40 - 42 43 - 45 46 - 48 49 - 52 25 Meeting the Challenge – Immediate Steps Build cancer network to make available nationally Early screening Rapid diagnosis Access to treatment Distributed clinic model Cancer centres Local clinics Mobile clinics Multidisciplinary teams Private and confidential Best-in-class equipment Ground-breaking therapies 26 Distributed Clinic Model C C M M Cancer Centre • Comprehensive cancer care • Best in class • Referral from local clinics C Cancer Centre C C Local Clinics Cancer Centre Algerian Cancer Council Cancer Centre Private and confidential Cancer Centre • Screening / diagnosis • Treatment M Mobile Clinics • Screening / diagnosis • Treatment Cancer Centre Linked to leading UK Cancer Institutions 27 Best-in-Class Cancer Centres Peter MacCallum Cancer Institute, Melbourne (cgi) Karolinska Institute Oxford Cancer Centre, Churchill Hospital Memorial Sloan Kettering, New York Private and confidential Guys and St Thomas’ Cancer Centre London (cgi) Mayo Clinic, Rochester Local Cancer Clinics – screening, diagnosis, treatment Jackson County, Oklahoma Billings, Montana Oxford Day Centre, Perth Cabrini Centre, Melbourne Ozark, Missouri Private and confidential Beatson West of Scotland Cancer Centre Cabrini Centre, Melbourne 29 Cancer Centres: The Excalibur Model Each cancer centre will have: • Rapid on site screening and diagnostics − Modern imaging techniques and molecular pathology − Clinical decision-making supported by excellent radiological opinion • World-class branded clinical and outpatient chemotherapy delivery − Delegation of responsibility to highly trained chemotherapy nurses − Support from oncology pharmacists − Molecular markers to improve precision of cancer treatment • Multidisciplinary team working to advanced guidelines and SOPs • Portable electronic patient data linked to national network • International second opinion service through link to Oxford Cancer Centre • Clinical Trial infrastructure Private and confidential 30 Advanced Infrastructure needed in the future Crick Institute (proposed) RadioImmuno targeting Lund Sweden Rinecker Proton Therapy Centre Munich Private and confidential Brooks-Wilson Genome Sciences Lab, British Columbia National Cancer Institute Rockville Maryland 31 Highly Advanced Mobile Screening Prostate Breast Mobile mammogram units Private and confidential 32 Nationwide Coverage via Mobile Treatment Protate Mobile Chemotherapy Units Private and confidential Mobile Radiation Therapy Units 33 Delivering Best in Class Cancer Patient Pathways • Co-develop global/local cancer care pathways & guidelines and protocols & multidisciplinary teams • Train and build capacity - clinic doctors/nurses/pharmacists • Telehealth services for diagnostic (complex cases, 2nd opinion) and training purposes with UK institutions • Develop cancer database (clinical outcomes) • Develop patient reported outcome measures (PROMs) • Develop app-based technology for side effect management, follow up etc • Patient education – wellness, nutrition, symptoms & treatment • Patient support and well being • Cancer prevention programs • Stratified analysis Private and confidential 34 Breast Cancer - Diagnosis Mammography - Royal Marsden Hospital, London Lauder Breast Cancer Centre, Sloan Kettering Mammography, Toronto Private and confidential Breast MRI Scan Cancer Research, London 35 Breast Cancer – Treatment Radiation Treatment UHN Toronto Endocrine Therapy Chemotherapy suite Private and confidential Lumpectomy, Mastectomy Conservation Surgery Adjuvant Systemic Treatment 36 Diagnosis Lung Cancer - Diagnosis CT Scan Royal Marsden Hospital, London Chest X-ray, Oxford University Hospitals, UK Private and confidential Sputum Cytology, Pathology laboratory, Princess Margaret Cancer Centre, Canada Bronchoscopy, Henry Ford Hospital, Detroit, USA 37 Lung Cancer – Treatment Robotic Lobectomy (surgery), Toronto General Hospital, Canada Chemotherapy, Targeted Drug Therapy, Royal Free Hospital, UK Private and confidential Radiotherapy, Peter MacCallum Cancer Centre, Australia Stereotactic Body Radiation Therapy (SBRT) Stanford Clinical Cancer Centre, USA 38 Diagnosis Colorectal Cancer - Diagnosis Endoscopy, Memorial Sloan Kettering Cancer Centre, USA Virtual Colonoscopy (CT scan), Guys’s & St Thomas’ Hospital, UK Private and confidential Fecal Occult Blood Test Fecal Immunochemical Test Flexible Sigmoidoscopy Odette Cancer Centre, Canada 39 Colorectal Cancer – Treatment Transanal endoscopic microsurgery- rectal tumor, Massachusetts General Hospital, USA Chemotherapym, Targeted Drug Therapy, John Hopkins Cancer Centre, USA Private and confidential External Radiotherapy, Addenbrooke’s Hospital, Cambridge, UK Colostomy Churchill Hospital, Oxford, UK 40 Specific Infrastructure Requirements • Build / set-up comprehensive cancer centres • Build / set-up network of local cancer clinics • Provide mobile clinics for screening, treatment and palliative care • Provide specialist equipment for radiotherapy, CT, PET, MRI, X-ray, US, Endoscopy, etc • Supply cancer drugs • Build immunological and molecular analysis facilities • Build nursing homes, residences and/or hospices • Provide eHealth tools for patient support and data Private and confidential 41 Detailed Manpower Requirements Histopathologists 930 Radiologist 1700 Haematologist 635 Palliative Care Physicians 215 Diagnostic radiographers 8400 Therapeutics radiographers 1515 Medical physicist 865 Based on current assumptions, not necessarily exhaustive. Private and confidential 42 A Modern Cancer Plan • Cancer Centres: 4 • Cancer Clinics: 8-12 • “Hub & Spoke” clinical model – fixed & mobile • Program budgeting • Tele-Health assessment • • • • • • National Cancer Network National Cancer Strategy Clinical guidelines Standardisation Clinical outcome analysis Need & benefit analysis Cancer database Structure & Governance World Class Cancer Care • Multi-disciplinary teams • Translational Medicines • Diagnostic & therapeutic equipment – fixed & mobile • Access to Expert Network / Key Opinion Leaders Infrastructure & Manpower Equitable & Quality Patient Care • Clinical Pathway Redesign • Screening, diagnosis & treatment • Mitigation of risk • Active management • Living with and beyond cancer • Sharing community experience 43 Investment Private and confidential 49 Professor Sir Christopher Evans OBE DSc, PhD, BSc, ARCS, F.Med.Sci, FR Eng, FRSC, FRSA, FIBiol, FIOM, CCMI, C.Biol., CSci, C.Chem